Pediatric & Juvenile Systemic Uveitis

Overview

Uveitis in children is a fundamentally different clinical problem than uveitis in adults. In an adult, anterior uveitis is usually a disease that announces itself — redness, pain, photophobia — and the patient's own symptoms are what trigger the visit to an ophthalmologist. In a child with juvenile idiopathic arthritis (JIA), the most common cause of pediatric uveitis, that entire mechanism is unreliable. The eye is typically white and quiet, the child has no pain, and neither the child nor a parent has any reason to suspect anything is wrong with the eye at all.

That gap between "disease is present" and "disease is noticed" is the organizing idea behind everything else on this page. Because JIA-associated uveitis so rarely announces itself through symptoms, ophthalmology cannot wait for a referral prompted by a red or painful eye — a child with an at-risk JIA subtype needs to be examined on a fixed schedule regardless of how their eyes feel. This is why routine, risk-stratified ophthalmologic screening — not symptom-driven care — is the accepted standard for children with JIA, and why the rheumatology-ophthalmology relationship in this disease is built around proactive surveillance rather than reactive consultation.

Clinical Features

The defining feature of JIA-associated anterior uveitis is that it is classically asymptomatic — a "quiet" uveitis with a white, comfortable-looking eye that gives no outward sign of the active inflammation happening on slit-lamp examination. This is the single most important thing to know about the disease, because it inverts the usual clinical logic: the absence of eye complaints in a child with JIA should never be treated as reassurance that the eyes are uninvolved.

Left undetected — which, given the silent presentation, generally means left unscreened — chronic anterior inflammation can smolder for months or years and cause real, often irreversible, structural damage. Well-recognized downstream complications of chronic, poorly controlled pediatric uveitis include band keratopathy (calcium deposition in the superficial cornea), posterior synechiae (adhesions between the iris and lens), cataract, and secondary glaucoma from chronic inflammatory changes to the angle. None of these complications requires a symptomatic eye to develop — they are exactly what routine screening exists to catch before they occur, rather than after.

Risk Stratification

Uveitis risk is not uniform across JIA — it varies substantially by subtype, antibody status, and age of disease onset, and that variation is what screening schedules are built around.

Oligoarticular JIA carries the highest risk of developing chronic anterior uveitis of any JIA subtype. Within oligoarticular JIA, the classic highest-risk profile is a young child — particularly a young girl — who is also ANA-positive. This combination of subtype, antibody status, age, and sex defines the population that ophthalmology and rheumatology treat as needing the closest surveillance.

Other JIA subtypes — systemic JIA, polyarticular RF-positive JIA, and enthesitis-related JIA — carry meaningfully lower uveitis risk than oligoarticular disease. They are not risk-free and still warrant ophthalmologic screening as part of standard JIA care, but the intensity and urgency of that screening is calibrated to be lower than for the oligoarticular, ANA-positive, young-onset profile described above.

Screening & Diagnosis

Because the disease itself gives no reliable warning sign, screening is the diagnostic strategy — not slit-lamp exams triggered by a complaint, but scheduled exams performed regardless of how the child's eyes appear or feel. The screening cadence is risk-stratified: a child's JIA subtype, ANA status, and age at disease onset together determine how frequently they need to be examined, with the oligoarticular, ANA-positive, young-onset profile above screened most intensively and lower-risk subtypes screened less often. Every newly diagnosed child with JIA should be referred to ophthalmology for baseline risk stratification and an initial exam regardless of subtype, since the screening interval itself depends on information only that exam and workup can establish.

On examination, the diagnosis is made by finding cells and flare in the anterior chamber on slit-lamp biomicroscopy — the same core finding as any anterior uveitis — in a child who, again, is very often reporting no ocular symptoms at all. This is why the exam itself, not the history, carries the diagnostic weight in this population.

Management

Initial management of JIA-associated uveitis centers on topical corticosteroids for acute control, with methotrexate established as the baseline steroid-sparing systemic agent for children who need ongoing disease control beyond topical therapy alone.

For disease that remains active despite methotrexate — refractory disease — the evidence-based next step is escalation to a biologic agent, and adalimumab, a TNF-alpha inhibitor, is the first-line biologic choice in this setting. This is grounded in the SYCAMORE trial, a randomized controlled trial that showed adding adalimumab to methotrexate reduced treatment failure and uveitis flares compared to methotrexate alone. SYCAMORE is the single piece of trial evidence most worth knowing by name in this disease, since it's what actually established adalimumab's role rather than adalimumab simply being tried empirically.

Related Topics

Continue exploring Systemic Disease & the Eye: